Head to Head Review: Genelux (NASDAQ:GNLX) versus Protagonist Therapeutics (NASDAQ:PTGX)Defense World · Oct 16, 2026
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed ImmunochemotherapyGlobeNewsWire · Sep 9, 2026
Genelux Corporation Reports Second Quarter Financial Results and Provides Business UpdatesGlobeNewsWire · Aug 13, 2026
Genelux (GNLX) Projected to Post Quarterly Earnings on ThursdayDefense World · Aug 5, 2026Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.20 | -$0.21 | Miss |
| May 7, 2026 | -$0.18 | -$0.20 | Miss |
| Mar 19, 2026 | -$0.22 | -$0.24 | Miss |
| Nov 5, 2025 | -$0.23 | -$0.21 | Beat |
| Aug 7, 2025 | -$0.22 | -$0.20 | Beat |
| May 6, 2025 | -$0.24 | -$0.21 | Beat |